Evaluation of the Genotoxic Potential of the Selective COX-2 Inhibitor Enflicoxib in a Battery of in vitro and in vivo Genotoxicity Assays

Abstract

Aim Enflicoxib, a selective COX-2 inhibitor approved for the treatment of pain and inflammation associated with osteoarthritis in dogs (Daxocox^® [Ecuphar/Animalcare Group]) was assessed for its genotoxic potential in a battery of in vitro and in vivo genotoxicity assays. These comprised a bacterial reverse mutation assay (Ames test), an in vitro human lymphocyte chromosome aberration assay and an in vivo mouse bone marrow micronucleus assay.

Methods Relevant vehicle and positive control cultures and animals were included in all assays. In the Ames test, enflicoxib was tested at concentrations of up to 5000 μg/plate. Signs of cytotoxicity were observed at the highest tested concentrations for several of the bacterial strains, both in absence and presence of S9. In human lymphocytes, enflicoxib was assessed for the induction of chromosomal aberrations when exposed at concentrations of up to 62.5 (3 hours) and 29.6 µg/mL (20 hours) in the absence of S9, and up to 66.7 µg/mL (3 hours) in presence of S9. Signs of cell toxicity, evidenced as a decrease in the mitotic index, were observed at these concentrations. In the mouse micronucleus assay, enflicoxib dose levels of up to 2000 mg/kg were administered (single dose) to male and female animals, and bone marrow samples were taken 24 and 48 hours (high-dose animals only) after administration.

Results Enflicoxib was shown to lack genotoxic activity in the conducted assays.

Conclusions The administration of enflicoxib as a therapeutic analgesic agent would not pose a genotoxic risk to animals or humans.

Key words

Enflicoxib - Daxocox - Genotoxicity - Mutagenesis - COX-2

Publikationsverlauf

Eingereicht: 31. August 2021

Angenommen: 16. November 2021

Artikel online veröffentlicht:
18. Januar 2022

• References

• 1 Wagemakers M, van der Wal GE, Cuberes R. et al. COX-2 inhibition combined with radiation reduces Orthotopic Glioma outgrowthby targeting the tumor vasculature. Transl Oncol 2009; 2: 1-7
• 2 EMA. European Medicines Agency. Daxocox. European Public Assessment Report (EPAR). July 16^th 2021. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/daxocox
• 3 Salichs M, Badiella L, Sarasola P. et al. Efficacy and safety of enflicoxib for treatment of canine osteoarthritis: A 6-week randomised, controlled, blind, multicentre clinical trial. Vet Rec 2021; e949 Epub ahead of print. PMID: 34590318.
• 4 Homedes J, Salichs M, Guzman A. Long-term safety evaluation of Daxocox® tablets (enflicoxib) in dogs after weekly oral administrations for seven months. BMC Vet Res 2021; 17: 205 PMID: 34082759; PMCID: PMC8173827.
• 5 ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. December 2009. EMA/CPMP/ICH/286/1995 https://www.ema.europa.eu/en/ich-m3-r2-non-clinical-safety-studies-conduct-human-clinical-trials-pharmaceuticals
• 6 VICH GL33 Guideline on studies to evaluate the safety of residues of veterinary drugs in human food: general approach to testing. EMEA/CVMP/VICH/486/02-Rev.2. 20 april 2009 https://www.ema.europa.eu/en/vich-gl33-safety-studies-veterinary-drug-residues-human-food-general-approach-testing
• 7 ICH S2(R1) (2012) Genotoxicity testing and data interpretation for pharaceuticals intended for human use. June 2012. EMA/CHMP/ICH/126642/2008 https://www.ema.europa.eu/en/ich-s2-r1-genotoxicity-testing-data-interpretation-pharmaceuticals-intended-human-use#current-effective-version-section
• 8 VICH GL23: Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Genotoxicity Testing. 6 November 2014 EMA/CVMP/VICH/526/2000 https://www.ema.europa.eu/en/vich-gl23-studies-evaluate-safety-residues-veterinary-drugs-human-food-genotoxicity-testing
• 9 Maron DM, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutat Res 1983; 113: 173-215 PMID: 6341825.
• 10 Organization for Economic Co-operation and Development (OECD). OECD guideline for testing of chemicals, No. 471. Genetic Toxicology: Bacterial Reverse Mutation Test. 2020
• 11 Dean BJ, Danford N. Assays for the detection of chemically-induced chromosome damage in cultured mammalian cells, in: S.Venitt, J.M.Parry (Eds.), Mutagenicity Testing: A practical approach. IRL Press; Oxford: 1984. pp. 187-232
• 12 Organization for Economic Co-operation and Development (OECD). OECD guideline for testing of chemicals, No. 473. Genetic Toxicology: In vitro mammalian chromosome aberration test. 1997
• 13 An International System for Human Cytogenetic Nomenclature (1985) ISCN 1985. Report of the Standing Committee on Human Cytogenetic Nomenclature, Birth Defects Orig.Artic.Ser., 21, (1985) 1-117. PMID: 4041569.
• 14 Richardson C, Williams JA, Allen JA. et al. Analysis of data from in vitro cytogenetic assays, in: Statistical evaluation of mutagenicity test data, (UKEMS Guidelines subcommittee report, Part III), D.J. Kirkland. Cambrige University Press; 1989. pp. 141-154
• 15 Schmid W. The micronucleus test. Mutat Res 1975; 31: 9-15 PMID: 48190.
• 16 Organization for Economic Co-operation and Development (OECD). OECD guideline for testing of chemicals, No. 474. Genetic Toxicology: Mammalian erythrocyte micronucleus test. 1997
• 17 Parliament E, Council E. 2010; DIRECTIVE 2010/63/EU on the protection of animals used for scientific purposes. EU Off. J L276
• 18 Generalitat de Catalunya. (1997) DECRET 214/1997, of July 30th, on the regulation of the use of animals for animal experimentation and other scientific purposes. DOGC num. 2450.
• 19 Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Statist Assoc 1955; 50: 1096-1121
• 20 Committee for medicinal products for veterinary use (CVMP). European Medicines Agency. Guideline on user safety for pharmaceutical veterinary medicinal products EMA/CVMP/543/03-Rev.1 15 March 2010 https://www.ema.europa.eu/en/user-safety-pharmaceutical-veterinary-medicinal-products
• 21 NDA Celecoxib 20-998, Celebrex (Celecoxib) Capsules 12/31/1998. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20998.cfm
• 22 NDA Valdecoxib 21-341, Bextra (Valdecoxib) Tablets 11/16/01. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra.cfm
• 23 Hilliard CA, Armstrong MJ, Bradt CI. et al. Chromosome aberrations in vitro related to cytotoxicity of nonmutagenic chemicals and metabolic poisons. Environ Mol Mutagen 1998; 31: 316-326 PMID: 9654240.
• 24 EMEA, Dynastat, INN-Parecoxib CPMP/1166/02 1/20 EMEA 2004 Scientific Discussion, (2004) www.ema.europa.eu/ema/pages/includes/document/opendocument.jsp?webContentId=WC500038649
• 25 Müller L, Kikuchi Y, Probst G. et al. 1999; ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact. Mutat. Res. 436: 195-225
• 26 Tweats DJ, Blakey D, Heflich RH. et al. 2007; Report of the IWGT working group on strategy/interpretation for regulatory in vivo tests II. Identification of in vivo-only positive compounds in the bone marrow micronucleus test. Mutat. Res 627: 92-105
• 27 Homedes J, Salichs M, Solà J. et al. Pharmacokinetics of enflicoxib in dogs: Effects of prandial state and repeated administration. J Vet Pharmacol Ther 2021; Epub ahead of print. PMID: 34160092.